FDA accepts filing of sNDA for Nuplazid to treat hallucinations and delusions associated with dementia-related psychosis.Acadia Pharma
Acadia Pharmaceuticals Inc.announced that the FDA has accepted for filing its supplemental New Drug Application (sNDA) for Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with… read more.